Medical Decision Making

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Litvak, E.
Right arrow Articles by Weinstein, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Litvak, E.
Right arrow Articles by Weinstein, M. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Medical Decision Making, Vol. 17, No. 4, 455-463 (1997)
DOI: 10.1177/0272989X9701700411


Other

Whose Blood Is Safer?

The Effect of the Stage of the Epidemic on Screening for HIV

Eugene Litvak, PhD

Joanna E. Siegel, ScD

Stephen G. Pauker, MD

Marc Lallemant, MD

Harvey V. Fineberg, MD, PhD

Milton C. Weinstein, PhD

Background. With improvements in HIV antibody test (ELISA) performance, the win dow of time between infection and seroconversion becomes a major source of error in HIV screening. The authors examined its impact on the false-reassurance rate (FRR). Methods. Test sensitivity was modeled as the product of two factors: the in herent sensitivity (sensitivity when antibody is present) and the probability that antibody is present in infected blood. A model of HIV and AIDS incidence was used to derive an estimate of the probability of remaining in the seronegative window (pw) among those who are infected. With plausible assumptions, this probability approaches 0.03. The FRR was then estimated as a function of the probability of remaining in the se ronegative window, the prevalence of HIV, and the inherent sensitivity of the ELISA test were estimated. Results. The FRRs for two blood donor groups, one with an HIV prevalence of 0.004 and a typical probability of remaining in the seronegative window (pw = 0.03) and the other with a higher prevalence of 0.017 but fewer donors in the window (pw = 0.003), are equal (140 per million donors) if the blood is negative on a single ELISA test. After two negative tests or a single test that can detect antibody more reliably, however, the FRR is much higher in the group with the higher pw (= 120 per million compared with 50 per million), because the greater numbers of donors in the window more than offsets the lower prevalence. Conclusions. With improvements in inherent sensitivity of ELISA by virtue of technical progress or retesting, the preva lence of HIV infection may no longer play the critical role in degrading the results of blood screening. As inherent test performance improves, tests are increasingly likely to miss infected blood because of the seronegative-window error rather than because of measurement error. Window error plays a proportionally greater role during the early stages of HIV dissemination in a population where the incidence of new HIV infection is high relative to the incidence of AIDS. These findings may explain, in part, the recent observation that cases of transfusion of contaminated blood often take place in areas where AIDS epidemics have started recently. They also suggest that the traditional strategy of soliciting blood donors from low-prevalence populations may not always be optimal, unless such populations are truly low-risk. Key words: HIV; AIDS; prevalence; incidence; sensitivity; ELISA; predicted values; protocols of screening; false-reassur ance rate. (Med Decis Making 1997;17:455-463)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Med Decis MakingHome page
J. M. Mrus, M. S. Yi, M. H. Eckman, and J. Tsevat
The Impact of Expected HIV Transmission Rates on the Effectiveness and Cost of Ruling Out HIV Infection in Infants
Med Decis Making, October 1, 2002; 22(5_suppl): S38 - S44.
[Abstract] [PDF]